AbCellera Biologics (ABCL) Tax Provisions (2021 - 2023)
Historic Tax Provisions for AbCellera Biologics (ABCL) over the last 3 years, with Q4 2023 value amounting to -$1.5 million.
- AbCellera Biologics' Tax Provisions rose 441.08% to -$1.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$27.6 million, marking a year-over-year decrease of 13429.18%. This contributed to the annual value of -$37.5 million for FY2024, which is 3585.47% down from last year.
- According to the latest figures from Q4 2023, AbCellera Biologics' Tax Provisions is -$1.5 million, which was up 441.08% from -$10.7 million recorded in Q3 2023.
- In the past 5 years, AbCellera Biologics' Tax Provisions registered a high of $62.2 million during Q1 2022, and its lowest value of -$10.7 million during Q3 2023.
- For the 3-year period, AbCellera Biologics' Tax Provisions averaged around $9.9 million, with its median value being -$776500.0 (2022).
- As far as peak fluctuations go, AbCellera Biologics' Tax Provisions skyrocketed by 65576.28% in 2022, and later plummeted by 730198.02% in 2023.
- AbCellera Biologics' Tax Provisions (Quarter) stood at $24.8 million in 2021, then plummeted by 106.13% to -$1.5 million in 2022, then rose by 4.41% to -$1.5 million in 2023.
- Its Tax Provisions was -$1.5 million in Q4 2023, compared to -$10.7 million in Q3 2023 and -$7.5 million in Q2 2023.